Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst

Aardvark Therapeutics said it dosed the first patient in Australia in its Phase 3 HERO trial of oral ARD-101 for hyperphagia in Prader‑Willi syndrome and has regulatory clearance to enroll sites in Canada and the U.K., advancing the program toward a William Blair‑expected topline readout in Q3 2026. William Blair initiated coverage with an Outperform, highlighting a roughly $10 billion PWS TAM and a larger opportunity for planned combination ARD‑201 (oral ARD‑101 + DPP‑4 inhibitor) that the firm pegs at least $100 billion as a potentially more tolerable oral alternative to GLP‑1RAs, and called out a valuation disconnect versus Aardvark’s $304 million market value. The company had $126.4 million in cash and short‑term investments, which management says should fund operations into 2027; shares were trading down about 6.3% at $14.63 at publication.

Analysis

Aardvark Therapeutics advanced its lead program by dosing the first patient in Australia in the Phase 3 HERO trial of oral ARD-101 for hyperphagia in Prader-Willi syndrome and has secured regulatory clearance to enroll sites in Canada and the U.K.; William Blair says U.S. enrollment remains strong and projects a topline readout in Q3 2026. William Blair initiated coverage with an Outperform and quantifies the PWS total addressable market at roughly $10 billion, noting there is currently only one approved treatment and arguing the program’s potential supports a valuation higher than the current market cap.

The firm also highlights a second program, ARD-201 (fixed-dose ARD-101 + DPP-4 inhibitor), which William Blair estimates could address a substantially larger opportunity (at least $100 billion) as an oral, more tolerable alternative to GLP-1RAs; management is running separate trials for obesity-related indications, creating multiple shots on goal. William Blair explicitly calls out an “appreciable disconnect” between Aardvark’s $304 million market value and the potential of ARD-101.

Aardvark reported $126.4 million in cash, equivalents and short-term investments, which the company says funds operations into 2027; shares traded down about 6.28% to $14.63 at publication. The balance sheet appears sufficient to support late-stage execution but commercialization and broader obesity programs would likely require additional capital, and the investment thesis remains binary on Phase 3 outcomes and regulatory progress.

Key Decisions for Investors

• Consider initiating or modestly increasing a long position to capture upside ahead of the Q3 2026 topline catalyst, while sizing exposure conservatively given binary Phase 3 risk
• Monitor enrollment cadence and regulatory site activations in Canada and the U.K. and any safety/interim signals closely, as positive operational updates should be primary near-term catalysts
• Track cash burn and financing commentary given $126.4 million runway into 2027 and plan for potential dilution if the company pursues commercialization or the larger ARD-201 development path
• For event-driven traders, consider hedged strategies (e.g., collars or protective puts) into the Phase 3 readout to manage downside from a negative result while retaining upside exposure